From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Signal Transduction and Targeted Therapy (2022) 7:20

Dear Editor,

Antibody–drug conjugates (ADCs), famous as biological targeting prodrugs, are gradually revolutionizing clinical cancer therapy. However, less than 1% of the dosed ADCs accumulate in the tumors.1 Therefore, the nonspecific release of the highly toxic payload (MMAE et al, 10−12−10−10 M) is a real threat, which could induce severe off-target toxicity.2 This danger necessitates strict requirements for the design of the linker. To date, the mainstream release problem,3 because their cleaving enzymes are widely distributed, all face this nonspecific release problem,2 because their cleaving enzymes are widely distributed with no significant difference in their quantities between tumor tissues and normal tissues.

Hypoxia, as the most important feature of the solid tumor microenvironment, has always been a target of drug discovery programs.4 Hypoxia can lead to the upregulation of nitroreductase (NTR), which has been detected at levels 100–1000-fold higher than that in normoxic cells.5 The most important function of NTR is to reduce the nitro group to an amino group under hypoxia rather than normoxia.6

In this work, a novel ADC design strategy was proposed. Based on the traditional antibody targeting the “prodrug”, we further utilized hypoxia-specific drug release to design an ADC as a “pro-prodrug”, achieving a superior therapeutic index (Fig. 1a). More specifically, in tumor tissues (O2% < 1%), the novel nitroaromatic-containing linker was activated by the NTR to smoothly release the active drug. Notably, the beauty of this strategy is that in normal tissues (O2% > 10%), the pro-prodrug was metabolized and stably remained in the low toxicity and low permeability prodrug form (Cys-linker-payload), which was crucial to reduce off-target toxicity.

Two classical hypoxia-sensitive groups, p-nitrobenzyl and nitromidazole, were chosen to develop p-nitrobenzyl-based linkers (1, 2, 3, and 4) and a nitromidazole-based linker (5). Corresponding ADCs (mil40-1/2/3/4/5) were generated by conjugating monomethyl auristatin E (MMAE) to an anti-HER2 antibody (mil40) through the above linkers (Supplementary Fig. S1). Traditional valine-citrulline-ADC (mil40-6, Supplementary Fig. S1) and valine-alanine-ADC (mil40-7, Fig. S1) were also synthesized as controls.

To quickly verify their potency, hypoxia-sensitive ADCs were evaluated for their cytotoxicity against the HER2+ cell lines NCI-N87, BT-474, and HCC1954 under hypoxia (0.1% O2, Fig. 1b, Supplementary Fig. S2). Excitingly, mil40-5 exhibited a significantly higher activity than other ADCs. The EC50 values were between 0.00012 nM and 0.46 nM, which were similar to that of the control ADC (mil40-6, Table S1). Mil40-5 was also confirmed to be HER2-specific, with low activity against HER2− cell lines (EC50 > 100 nM, Supplementary Fig. S2). Only 5.8%, 18.5%, 56.1%, 62.7% of MMAE released from p-nitrobenzyl-based linkers explained the poor efficacies of ADCs mil40-1/2/3/4/5, (Supplementary Fig. S3a, b, c). The generation and characterization of the optimal ADC mil40-5 are shown in the supplementary materials (Supplementary Fig. S4a, b, c, d, e). Liquid chromatography-mass spectrometry analysis showed an average drug-to-antibody ratio (DAR) of 4.0 for mil40-5 (Fig. 1c).

Flow cytometry analysis and laser confocal microscopy revealed the binding and subsequent endocytosis into lysosomes (Pearson correlation coefficient = 0.918, Fig. 1d, e).

The hypoxia cytotoxicity ratio (HCR) is the gold standard for hypoxia-sensitive drugs. Significantly, mil40-5 showed oxygen concentration-dependent cytotoxicity (Fig. 1b). In Herceptin-sensitive cells, the EC50 value under hypoxia (1% O2, EC50 = 0.025 nM) was 10 times lower than that under normoxia (10% O2, EC50 = 0.23 nM). In Herceptin-resistant cells, the HCR further increased, reaching as much as 27 (0.73 nM vs. 19.48 nM), owing to the shielding of antibody activity. For highly toxic payloads, this ten-fold difference was important for improving the therapeutic index of ADCs. Additionally, the maximum inhibition rate increased with prolonged hypoxia culture time, which provided further evidence for hypoxia activation of mil40-5 (Fig. 1b).

Under normoxia, mil40-5 was metabolized and stably existed as the prodrug Cys-5 (21% O2, Supplementary Fig. S5a). Both mil40-5 and N-acetyl-l-cysteine (NAC)-5 exhibited excellent stability in plasma and under physiological ionic conditions, with less than 2% of MMAE released (Fig. 1f, Fig. S5b). Furthermore, NAC-5 demonstrated good liver microsome stability with 77% unchanged (Fig. 1g) and no MMAE released (Supplementary Fig. S5c), indicating reduced hepatotoxicity. As designed, Cys-5 significantly reduced cytotoxicity by 51–78 times compared with MMAE (Fig. 1h). This was due to the decreased tubulin inhibitory activity of Cys-5 compared to MMAE, with EC50 values of 8.784 μM and 1.259 μM (Fig. 1i, Fig. S5d). Interestingly, the efficacy of Cys-5 under hypoxia was also not enhanced (Supplementary Fig. S5e), which was due to the limited permeability of Cys-5 (MloP = -1.818, Supplementary Table S2). The above results suggested that mil40-5 could reduce off-target toxicity in normal tissues through the stable, low toxicity prodrug Cys-5 (Supplementary Fig. S5f).

Under hypoxia, mil40-5 smoothly released the active drug MMAE in BT-474 and NCI-N87 cells (0.1% O2, Supplementary Fig. S6a). More precisely, approximately 90% MMAE was effectively released within 24 h under hypoxia with NTR, which was far more than that in normoxia and hypoxia without NTR (<10%, Fig. 1j). Meanwhile, other common physiological ions did not lead to the significant release of free MMAE, which verified the NTR specificity of the linker (Fig. 1k). MMAE induced cell cycle arrest in the G2/M phase and eventually led to apoptosis. When treated with mil40-5 (10 nM, 0.1% O2), the percentage of BT-474 cells in the G2/M phase increased from 10.78 to 82.75%, and the apoptosis percentage increased from 10.78 to 82.75% (Fig. 1l). Similar trends were also observed in NCI-N87 cells (Supplementary Fig. S6b).

Received: 21 July 2021 Revised: 22 September 2021 Accepted: 14 November 2021
Published online: 21 January 2022

© The Author(s) 2021
The above results suggested that mil40-5 exerted cytotoxicity through the hypoxia-NTR-specific release of MMAE (Supplementary Fig. S6c).

Encouraged by the in vitro results, the therapeutic potential of the preferred mil40-5 was then determined in BT-474 and NCI-N87 mouse models. In BT-474 mouse model, mil40-5 exhibited better efficacy than mil40 combined with MMAE (Supplementary Fig. S7a), and showed significant tumor growth inhibition at 6 mg/kg ($p < 0.0001$, Fig. 1n). More importantly, four doses of 6 mg/kg mil40-5 induced tumor regression in five out of six mice,
exhibiting better efficacy than docetaxel at 10 mg/kg (p = 0.0012, Supplementary Fig. S7a). In the NCI-N87 mouse model, mil40-5 also exhibited better efficacy than mil40 at the dose of 5 mg/kg (p = 0.009, Fig. 1n). In addition, mil40-5 was expected to achieve better efficacy through combined use of docetaxel (p = 0.0007, Supplementary Fig. S7b). Then, the targeting effect in vivo was confirmed by in vivo imaging analysis. The fluorescence-labeled mil40 and mil40-5 were initially visualized in the tumor sites within 24 h, and the tumor-located image was clearly maintained over 10 days (Fig. 1o).

Finally, we explored the safety advantages of mil40-5 in CD-1 mice. The maximum tolerable dose (MTD) of mil40-5 was not reached even at the extremely high dosage of 160 mg/kg, and it showed no obvious signs of toxicity or body weight loss (Fig. 1p, Supplementary Fig. S8a). In comparison, mice in the control ADC (mil40-7) group began to experience sustained weight loss (0–5 days) at 80 mg/kg (Fig. 1p). When tested at a treatment dose (20 mg/kg), mice in the mil40-5 group did not show significant tissue lesions. However, an additional increase in hepatocyte mitoses was observed in H&E staining of the liver and grain-red ratio in the control ADC (mil40-6) and mil40-1:MMAE groups, indicating potential hepatotoxicity (Fig. 1q, Supplementary Fig. S8b).

In conclusion, the first hypoxia-sensitive ADC was developed as a pro-drug. It was based on a novel nitroimidazole-based linker, realizing oxygen-dependent cytotoxicity. A 27-fold cytotoxicity enhancement was observed when the ADC was activated by hypoxia. This controllable cytotoxicity further transformed into significant efficacy and a superior therapeutic index in vivo. A significantly higher MTD (>160 mg/kg) was obtained compared with traditional ADC (<80 mg/kg). This novel strategy could be universally applied to existing payloads and different antibodies, which represent next-generation ADCs.

DATA AVAILABILITY
All relevant data are available in Supplementary Information and from the authors.

ACKNOWLEDGEMENTS
This work was funded by the Chinese National Natural Science Foundation (grant number 81372736 and 81903451), and the China Postdoctoral Science Foundation (grant number 2019M664015).

AUTHOR CONTRIBUTIONS
S.L., W.Z., and X.Z. conceived the project. Y.W. and J.L. designed the experiments and executed the chemical synthesis. Y.W. and S.F. performed the pharmacodynamic experiments. D.X. and F.X. analyzed the data. Y.W. and D.X. wrote the paper. All of the authors discussed the results and commented on the manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material at https://doi.org/10.1038/s41392-021-00833-8.

Competing interests: The authors declare no competing interests.

Yanning Wang1,2, Jianqiu Li2, Shiyong Fan1, Fei Xie1, Wu Zhong1, Xinbo Zhou2 and Song Li1
1National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850 Beijing, China and 2Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022 Hangzhou, Zhejiang, China
These authors contributed equally: Yanning Wang, Jianqiu Xiao, Xinbo Zhou.
Correspondence: Wu Zhong (zhongwu@bmi.ac.cn) or Xinbo Zhou (zhouxinbo@bmi.ac.cn)

REFERENCES
1. Teicher, B. A. & Chari, R. V. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17, 6389–6397 (2011).
2. Su, Z. et al. Antibody–drug conjugates: recent advances in linker chemistry. Acta Pharm. Sin. B https://doi.org/10.1016/j.apsb.2021.03.042 (2021).
3. Bargh, J. D., Isidro-Lloret, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody-drug conjugates. Chem. Soc. Rev. 48, 4361–4374 (2019).
4. Sharma, A. et al. Hypoxia-targeted drug delivery. Chem. Soc. Rev. 48, 771–813 (2019).
5. Fang, Y., Shi, W., Hu, Y., Li, X. & Ma, H. A dual-function fluorescent probe for monitoring the degrees of hypoxia in living cells via the imaging of nitroreductase and adenosine triphosphate. Chem. Commun. (Camb). 54, 5454–5457 (2018).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021